12:00 AM
 | 
Sep 16, 2013
 |  BC Week In Review  |  Company News  |  Other News

Transcept, Purdue Pharma neurology news

Two shareholders sent letters to Transcept's board saying they do not believe Transcept's plan to acquire a new product, along with its associated costs and risks, are in the best interests of shareholders. In its 2Q13 earnings, Transcept said it is "conducting an extensive new product search and evaluation process" and believes that by the end of the year it "will be able to announce progress in re-building our development pipeline."

The company's largest shareholder, Roumell Asset...

Read the full 368 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >